A roundup of some of the latest scientific studies on the novel coronavirus and efforts to find treatments and vaccines includes a higher complication rate with Covid-19 versus the flu.
Pfizer Inc. and BioNTech SE announced the start in Japan of combined Phase I and Phase II clinical trials of their mRNA vaccine candidate against the novel coronavirus.
German biotech company Evotec said on Monday the company had received a grant from the Bill & Melinda Gates Foundation to help identify and develop potential monoclonal antibody (mAbS) drugs for the prevention of severe Covid-19.
Gilead Sciences Inc.’s remdesivir had little or no effect on Covid-19 patients’ length of hospital stay or chances of survival, a clinical trial by the World Health Organization (WHO) found.
South Korean drugmaker Daewoong Pharmaceutical Co. Ltd. received regulatory approval for Phase 1 clinical trials of the company’s anti-parasitic niclosamide drug to treat Covid-19 patients.
The U.S. government awarded $486 million to AstraZeneca Plc to develop and secure supplies of up to 100,000 doses of Covid-19 antibody treatment, a similar class of drug that was used in treating President Donald Trump.
Pfizer’s Phase III study assessing Ibrance as a potential treatment for early breast cancer patients who have residual invasive disease following neoadjuvant chemotherapy failed to meet the clinical trial’s primary endpoint.
Swedish Orphan Biovitrum (Sobi) announced that the rare disease drug maker’s phase 3 study of avatrombopag did not meet the clinical trial’s primary endpoint, sending the company’s shares sharply down.
Allele Biotechnology and Pharmaceuticals filed lawsuits against Regeneron Pharmaceuticals, as well as Pfizer and Germany’s BioNTech, claiming the companies infringed on Allele’s patented mNeonGreen technology in the development of their Covid-19 treatments.
Amgen presented five-year Phase II data in episodic migraines at the Migraine Trust Virtual Symposium showing that the anti-CGRP medication Aimovig helped patients achieve sustained reductions in monthly migraine days.